Coreline Soft, a leading company specializing in medical AI, announced on July 28 that it has successfully registered a U.S. patent for a core technology aimed at improving the trustworthiness of AI systems.
The patented technology is titled “Medical Neural Network-Based Medical Image Analysis Device and Method for Evaluating the Analysis Results of Medical Neural Networks,” and it has been officially registered with the United States Patent and Trademark Office (USPTO). The company has also received the patent certificate.
This technology involves a supplementary neural network system, often described as “AI evaluating AI,” where one AI verifies or assesses the inference results (such as lesion detection outcomes) produced by another AI. It is designed to complement conventional single AI diagnostic models and provides users with an evaluation of the inference results, thereby enhancing trust and clinical applicability.
Amidst the global regulatory emphasis on ‘trustworthy (explainable and reliable)’ AI systems by agencies such as the FDA and European EMA, Coreline Soft’s recent patent is gaining attention as a technology aligned with international regulatory trends. Particularly, it is regarded as a crucial validation method in “Human-in-the-loop” AI systems, which are vital for practical application in clinical settings.
The patent was developed by four inventors from Coreline Soft, including CEO Kim Jin-guk, Research Director Lee Jae-yeon, Senior Researcher Yoo Dong-hun, and Lead Researcher Seo Hyun-ki. It was granted through a divisional application process from an existing patent. Significantly, the scope of the patent extends beyond medical imaging, encompassing general image analysis, which opens the potential for applications in manufacturing, industrial security, aerospace imaging, and other non-medical fields. This broad applicability highlights its potential as a “trust-based AI platform” with extensive technological impact.
Lee Jae-yeon, head of Coreline Soft's research division, stated, “This patent registration demonstrates that our AI solutions are evolving beyond simple automation tools to support precise and safe medical decision-making.” He added, “Securing both technological competitiveness and intellectual property rights in the global market will strengthen our corporate value and IPR assets.”
In addition, Coreline Soft is actively pursuing certifications and commercialization in more than 20 countries—including the U.S., Europe, and Japan—with its AI diagnostic platform ‘AVIEW LCS Plus,’ which can analyze lung cancer, COPD, and coronary artery disease simultaneously.
List